Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of Glucagon-like peptide-1 (GLP-1) in respect to gastric emptying, appetite and food intake.

The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the researchers will investigate individuals with and without intact nervous supply.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Gentofte, Copenhagen
• Collaborator: University of Copenhagen
• Treatments: Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• truncal vagotomy

• normal hemoglobin

• informed consent

• Age, gender and weight matched controls

• normal hemoglobin

• informed consent

Exclusion Criteria:

• type 1 diabetes mellitus or type 2 diabetes mellitus

• body mass index > 30 kg/m2

• inflammatory bowel disease

• intestinal resection

• nephropathy (serum creatinine > 150 µM and/or albuminuria)

• liver disease (ALAT and/or ASAT > 2 x normal value)

• treatment with medicine which cannot be paused for 12 hours